Alliance Pharma PLC Total Voting Rights (4669X)
10 August 2018 - 7:00PM
UK Regulatory
TIDMAPH
RNS Number : 4669X
Alliance Pharma PLC
10 August 2018
For immediate release 10 August 2018
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
Total Voting Rights
Alliance Pharma plc (AIM: APH), the specialty pharmaceutical
group, makes the following notification in accordance with the UK
Financial Conduct Authority's Disclosure and Transparency Rule
5.6.1.
As at 31 July 2018 the Company's issued share capital consists
of 515,127,294 Ordinary Shares of 1p each.
The total number of voting rights in the Company is 515,127,294
and this figure may be used by shareholders as the denominator for
the calculations by which they should determine if they are
required to notify their interest in, or change to their interest
in, the Company under the FCA's Disclosure Guidance and
Transparency Rules.
For further information:
Alliance Pharma plc
Peter Butterfield, Chief Executive Officer
Andrew Franklin, Chief Financial Officer
www.alliancepharma.co.uk + 44 (0) 1249 466966
Buchanan + 44 (0) 20 7466
Mark Court / Sophie Wills / Gemma Mostyn-Owen 5000
Numis Securities Limited
Nominated Adviser: Michael Meade / Freddie
Barnfield + 44 (0) 20 7260
Corporate Broking: James Black / Toby Adcock 1000
Investec Bank plc
Corporate Finance: Daniel Adams / Ed Thomas +44 (0) 20 7597
Corporate Broking: Patrick Robb / Rob Baker 5970
Notes to editors:
About Alliance Pharma
Alliance, founded in 1998, is an international specialty
pharmaceutical group based in Chippenham, Wiltshire, UK. The Group
has sales in more than 100 countries worldwide via direct sales,
joint ventures and a wide network of distributors. Alliance has a
strong track record of acquiring the rights to established niche
products and it currently owns or licenses the rights to
approximately 90 pharmaceutical and consumer healthcare products.
The Group continues to explore opportunities to expand its product
portfolio.
Alliance joined the AIM market of the London Stock Exchange in
December 2003 and trades under the symbol APH.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
TVRGGURCRUPRURU
(END) Dow Jones Newswires
August 10, 2018 05:00 ET (09:00 GMT)
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Apr 2024 to May 2024
Alliance Pharma (LSE:APH)
Historical Stock Chart
From May 2023 to May 2024